Replimune Group (NASDAQ:REPL) Shares Gap Down – Time to Sell?

Replimune Group, Inc. (NASDAQ:REPL)’s share price gapped down prior to trading on Monday . The stock had previously closed at $9.70, but opened at $8.69. Replimune Group shares last traded at $8.08, with a volume of 1,630,000 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a report on Friday, April 10th. Jefferies Financial Group reissued a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Cantor Fitzgerald lowered Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. JPMorgan Chase & Co. raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price on the stock in a research note on Friday, June 26th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.86.

Replimune Group Price Performance

The stock’s 50 day moving average price is $9.35 and its 200-day moving average price is $7.39. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $449.08 million, a PE ratio of -1.58 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities analysts forecast that Replimune Group, Inc. will post -2.44 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

A number of large investors have recently modified their holdings of the company. Breakwater Capital Group purchased a new position in Replimune Group during the 2nd quarter worth $220,000. Seven Fleet Capital Management LP bought a new stake in Replimune Group during the 1st quarter valued at $921,000. Essential Partners LLC lifted its holdings in shares of Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after buying an additional 5,624 shares during the period. Bank of America Corp DE lifted its holdings in shares of Replimune Group by 17.7% in the 1st quarter. Bank of America Corp DE now owns 253,449 shares of the company’s stock worth $1,939,000 after buying an additional 38,119 shares during the period. Finally, Readystate Asset Management LP bought a new position in shares of Replimune Group during the 1st quarter worth $1,059,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.